为什么在大流行期间参与国际临床试验平台很重要？在日本启动REMAP-CAP。
Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan.
作者信息
Kamata Kazuhiro, Jindai Kazuaki, Ichihara Nao, Saito Hiroki, Kato Hideaki, Kunishima Hiroyuki, Shintani Ayumi, Nishida Osamu, Fujitani Shigeki
机构信息
Department of General Internal Medicine, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Kawahigashimachi Tanisawa, Aizuwakamatsu-city, Fukushima, 969-3492, Japan.
Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Niigata city, Japan.
出版信息
J Intensive Care. 2021 Apr 14;9(1):34. doi: 10.1186/s40560-021-00547-7.
REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
社区获得性肺炎随机、嵌入式、多因素适应性平台试验（REMAP-CAP）是一项国际临床试验，为应对新冠疫情，其规模和范围正在迅速扩大。在日本学术团体的支持下，日本现正加入REMAP-CAP。参与REMAP-CAP可通过及时确定最佳的新冠治疗方法，为人群健康做出重大贡献。此外，它将与包括一线医护人员、政府机构、监管当局和学术团体在内的多个利益相关方合作，推动建立一个国家和全球临床试验网络，以应对未来新出现和再次出现的传染病大流行。
Zotero 插件